European launch and approval for additional indications of currently approved drugs will drive further growth. After a long steady decline and a biotech crash, Tesaro is now significantly undervalued.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
